Ratings Humana Inc.

Equities

HUM

US4448591028

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
305.9 ^USD	-1.77%		-6.83%	-33.18%

Apr. 26	Deutsche Bank Adjusts Price Target on Humana to $341 From $355	MT
Apr. 26	HCA beats first-quarter profit estimates on higher patient admissions	RE

Summary

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company shows low valuation levels, with an enterprise value at 0.37 times its sales.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
HUMANA INC.	-33.18%	36.86B	A-
ELEVANCE HEALTH, INC.	+13.93%	125B	A-
CIGNA	+18.37%	101B	B-
CENTENE CORPORATION	-0.28%	39.69B	B-
MOLINA HEALTHCARE, INC.	-5.28%	20.05B	B-
PROGYNY, INC.	-13.82%	3.08B	C+
ALIGNMENT HEALTHCARE, INC.	-39.49%	993M	B-
CLOVER HEALTH INVESTMENTS, CORP.	-28.58%	337M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes